Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.

Ava KwongVivian Yvonne ShinCecilia Y S HoChun Hang AuThomas P SlavinJeffrey N WeitzelTsun-Leung ChanEdmond S K Ma

Published in: BMC cancer (2020)

In view of the high lifetime risk of malignancy, identification of patients with germline TP53 mutations are important for clinicians to aid in accurate risk assessment and offer surveillance for patients and their families.

Keyphrases

risk assessment
end stage renal disease
ejection fraction
dna repair
newly diagnosed
public health
palliative care
prognostic factors
high resolution
patient reported outcomes
dna damage
human health